Product logins

Find logins to all Clarivate products below.


Autism Spectrum Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Autism Spectrum Disorder (US)

Autism spectrum disorder (ASD) is a complex, heterogeneous, neurodevelopmental disorder that involves significant social, communicational, and behavioral challenges. Behavioral and developmental therapies are the cornerstones of treatment. There is no cure for ASD, and pharmacological intervention is mainly focused on symptomatic management. Risperidone and aripiprazole are the only two FDA-approved drugs for the treatment of irritability associated with ASD; other drugs, such as antidepressants, stimulants, and antiepileptics, are used off-label to manage co-occurring psychiatric conditions. Our Treatment Algorithms study provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients, providing insight into the current treatment landscape for ASD.

Questions answered

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed ASD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed ASD patients?
  • How have atypical antipsychotics been integrated into the treatment algorithm, and what is their source of business?
  • What percentage of ASD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of ASD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall, using real-world, patient-level claims data, enabling you to:

  • Understand patient flow between lines of therapy.
  • Evaluate your brand share against competitors.
  • Accurately assess your source of business.
  • Quantify opportunities at different stages of the treatment algorithm.

Product enhancement

Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.

Content highlights

Publication date: April 2026

Geography: United States

Real-world data: U.S. pharmacy and medical claims data

Key drugs covered: Risperidone, aripiprazole, sertraline, methylphenidate HCl, fluoxetine

Key analyses:

  • Brand / therapy usage across longitudinal patient sample
  • Newly diagnosed patient analysis
  • Treatment initiation and progression
  • Line of therapy analysis
  • Combination therapy analysis
  • Source of business for recently treated patients
  • Persistency and compliance analysis
  • Product-level patient flow

Related Market Assessment Reports

Report
Systemic Lupus Erythematosus – Unmet Need – Unmet Need – Moderate to Severe Systemic Lupus Erythematosus (US/EU)
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…
Report
Systemic Lupus Erythematosus | Unmet Need | Moderate to Severe Systemic Lupus Erythematosus | US/EU | 2024
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…
Report
Dry and Wet Age-Related Macular Degeneration – Landscape & Forecast – Disease Landscape & Forecast (G7)
AMD is a leading cause of vision loss across the G7 markets, with wet AMD accounting for most drug-treated cases. The market is dominated by IVT therapies such as Avastin, Eylea, Vabysmo, and Eylea…
Report
Rheumatoid Arthritis – Unmet Need – Unmet Need – TNFi-Refractory Rheumatoid Arthritis (US/EU)
Rheumatoid arthritis (RA) patients who are refractory to one or more tumor necrosis factor (TNF)-alpha inhibitors are generally prescribed a non-TNF-targeted therapy (e.g., Bristol Myers Squibb’s…
Report
Chronic Urticaria – Unmet Need – Unmet Need – Chronic Urticaria (US/EU)
Treatment of CSU and CIndU is dominated by oral medications, including approved therapies such as first- and second-generation antihistamines and a range of off-label options (e.g.,…